SONY-DADC-BIOSCIENCES
MyCartis , the provider of fully integrated and broadly applicable molecular diagnostics and immunodiagnostics solutions, and Sony DADC BioSciences today announced the cooperation in the production of a microfluidic assay cartridge for MyCartis’ EvalutionTM digital multiplex analysis platform to support a range of applications in the clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160229005056/en/
Sony DADC BioSciences, a leading supplier of smart polymer parts for the biomedical industry, is using their ISO 13485-certified facility in Salzburg, Austria for manufacturing. The customized foil bonded cartridge is manufactured as a monolithic molded microtiter size plate that has optical transparency and combines macrostructures, high precision microstructures and filter structures for achieving the ultra-sensitivity of the EvalutionTM System.
“We are very pleased to be working with Sony DADC BioSciences as our development and manufacturing partner for the EvalutionTM cartridge. The collaboration between the two companies brings together a broad range of knowledge and experience, which are important for the success of innovative new technologies such as the EvalutionTM System,” said Joris Schuurmans, CEO of MyCartis.
The highly integrated assay cartridge contains reaction and detection chambers to ensure short time to result and minimal processing steps. Next to the ability to run 1 to 16 samples at the same time the EvalutionTM System further delivers superior data quality and rapid results.
“We are fascinated about MyCartis’ flexible EvalutionTM platform and enjoy our mutual team spirit. From a manufacturing perspective, the project enhances our capabilities in both injection molding and bonding of microfluidic consumables in micro titer plate format – the de facto industry standard,” said Werner Balika, Engineering Manager at Sony DADC BioSciences GmbH.
About MyCartis
MyCartis' innovative research and diagnostic system, called EvalutionTM , features the measurement and detection of molecular components of different nature (proteins, nucleic acids…), indicative of a specific pathological state in a multiplex format. The new semi-automated system is highly user-friendly thanks to its integrated workflow and provides rapid and robust results thanks to improved kinetics in the microfluidic channels. In addition, MyCartis develops ready-to-use multiplex assays with major clinical and compelling health economic values, through its own development efforts as well as through strategic partnerships. Oncology, neurology, cardiology and immunology are MyCartis' primary focus.
For more information please visit http://www.mycartis.net/
About Sony DADC BioSciences GmbH
Building on Sony DADC’s experience in high-precision optical disc manufacturing, Sony DADC BioSciences partners with Life Sciences and Diagnostics companies enabling the industrial manufacturing of smart polymer parts.
For more information please visit http://biosciences.sonydadc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160229005056/en/
Contact:
MyCartis NV
François Topin
+32 9 241 11 60
ftopin@mycartis.net
or
Sony
DADC BioSciences GmbH
Ricarda Pichler
+43 6246 880 8142
ricarda.pichler@sonydadc.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FES Super Extends Partnership with SS&C28.5.2025 00:13:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region. FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund. “Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver
Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 21:48:00 CEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release
~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom